481.78MMarket Cap-11.72P/E (TTM)
9.260High8.593Low11.35KVolume8.820Open8.780Pre Close100.39KTurnover0.11%Turnover RatioLossP/E (Static)52.03MShares14.99052wk High2.54P/B95.99MFloat Cap6.00052wk Low--Dividend TTM10.37MShs Float30.430Historical High--Div YieldTTM7.60%Amplitude5.050Historical Low8.843Avg Price1Lot Size
GH Research Stock Forum
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
GHRS
Share
• Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8
• Primary endpoint met in phase 2a POC t...
• $ACADIA Pharmaceuticals (ACAD.US)$ : Jefferies Upgrades to Buy from Hold - PT $25 (from $22)
• $Arthur J. Gallagher (AJG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $185 (from $182)
• $Apple Hospitality REIT Inc (APLE.US)$ : B.Riley Upgrades to Buy from Neutral - PT $19
• $AutoZone (AZO.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $2,420 (from $2,125)
• $Boeing (BA.US)$ : Citigroup Upgr...
No comment yet